Good morning and thank you. Patience, I guess is a virtue. But I wanted to follow up on a couple of questions on the Emerging Markets side. If you could talk a little bit about what products are gaining the most traction. And on the investment side, particularly in China, you had in this past quarter a deal announced on the R&D side, the establishment of a facility there. What is the longer-term goal on the R&D side? Is there a therapeutic goal? Is there some sort of technology that you''re looking for? Thank you.
Ian C. Read
So let me answer the commercial part first and then Martin can answer the R&D side. In China, its large part it is an out-of-pocket market, so brand loyalty and quality is really important. So we compete with a portfolio that we have accumulated over many years and products that are still growing, products like Norvasc and Lipitor and Zithromax. So frankly it is our total portfolio is growing and it is not as impacted as the United States or Europe is by LOEs.
So this requires what I would call a traditional investment thesis, feet on the street, field force, relationships with physicians, maintain your quality, be visible, invest in the market, invest with key opinion leaders and that is what we intend to do.
I will hand over to Martin on research.
Martin Mackay
Yes. Just briefly, David, we established R&D center in 2006. And initially it was to form collaborations with academics and some biotech companies. But more recently we have started our own portfolio, particularly in China, really dedicated to diseases that are prevalent in those areas. So you know yourself, from oncology to liver disease and the like. They have their own portfolio that they are progressing now. And I must say that the speed of progress is quite astounding in that timeframe.
Jeffrey B. Kindler
Okay. Thank you all very much. Thank you for joining us today. Have a good day.
|
More:
